{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-141795","form_type":"8-K","ticker":"LYEL","cik":"0001806952","company_name":"Lyell Immunopharma, Inc.","filed_at":"2025-06-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.804598+00:00","generated_at":"2026-05-19T05:00:42.633472+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Lyell reports LYL314 Phase 1/2 data: 88% ORR, 72% CR in 3L+ LBCL","bullets":["In efficacy-evaluable 3L+ patients (N=25), ORR 88% (22/25) with 72% CR; median follow-up 9 months.","71% (10/14) of CR patients remained in CR at ≥6 months; no Grade ≥3 CRS; no deaths related to LYL314.","In 2L patients (N=11), ORR 91% with 64% CR; 100% of CR patients in CR at last assessment (3/3 at ≥6 months).","Plan to initiate randomized pivotal trial of LYL314 in 2L R/R LBCL by early 2026.","LyFE manufacturing center expected to support >1,200 CAR T doses annually for clinical and early commercial use."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-141795","json":"https://secwatch.observer/filing/0001193125-25-141795.json","markdown":"https://secwatch.observer/filing/0001193125-25-141795.md","text":"https://secwatch.observer/filing/0001193125-25-141795.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525141795/0001193125-25-141795-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806952/000119312525141795/d15114d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T05:00:42.633472+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}